Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success...
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical...
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA technology in wide array of...
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON, Aug. 15, 2023 (GLOBE...
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023...
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership...
Announced pricing of approximately $5 million equity financing (approximately $5.7 million if underwriter’s overallotment option is exercised in full); expected...
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on...
Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new...
Notice of Interim Results and WebcastGUILDFORD, SURREY / ACCESSWIRE / August 15, 2023 / ANGLE plc (AIM:AGL), (OTCQX:ANPCY), a world-leading...
Calgary, Alberta--(Newsfile Corp. - August 14, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce...
Data presented at the 2023 SNO/ASCO CNS Cancer ConferenceBerubicin currently being evaluated in an ongoing potentially pivotal study for the...
Stemtech Unveils Bold Vision ‘Grand China Market Plan' to Supercharge China's Thriving Health and Wellness Landscape Amidst $ 683 Billion...
Net revenue increased 36% in Q2 2023 versus Q1 2023Top line results expected late October 2023 for company's phase 3...
Combination study of SON-1010 with Roche's atezolizumab (Tecentriq®) has been initiated in AustraliaFirst SON-1010 Phase 1 study has been completed...
Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for...
LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Solve GNE announced today that it has entered into a sponsored research...
MSLs can now leverage the power of HCP Universe anywhere, at any time to enhance interactions with healthcare leadersNEW YORK,...
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023...